Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Marie Robin"'
Autor:
Marcus Ditschkowski, Mahmoud Aljurf, Juan Carlos Hernández-Boluda, Eibhlin Conneally, Donal P. McLornan, Marie Robin, Tomasz Czerw, Patrick Hayden, Nicholas C.P. Cross, Ibrahim Yakoub-Agha, H. Joachim Deeg, Nicola Polverelli, Mufaddal T. Moonim
Publikováno v:
Leukemia. 35:2445-2459
Allogeneic haematopoietic cell transplantation (allo-HCT) remains the only curative approach in myelofibrosis (MF). Despite advances over recent decades, relapse and non-relapse mortality rates remain significant. Relapse rates vary between 15 and 25
Autor:
Ibrahim Yakoub-Agha, Martin Bornhäuser, Nienke Zinger, Jaime Sanz, Jakob Passweg, Simona Iacobelli, Patrick Hayden, Riitta Niittyvuopio, Juan Carlos Hernández-Boluda, Peter Dreger, Emanuele Angelucci, Nicolaus Kröger, Jan J. Cornelissen, Antonin Vitek, Arturo Pereira, Tomasz Czerw, Tsila Zuckerman, Dietrich W. Beelen, Marie Robin, Eefke Petersen, Igor Wolfgang Blau, Donal McLornan, Jürgen Finke, Lothar Kanz
Publikováno v:
LEUKEMIA
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
Leukemia, 35(1), 215-224. Nature Publishing Group
Leukemia
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
Leukemia, 35(1), 215-224. Nature Publishing Group
Leukemia
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
We aimed to evaluate the determinants of survival in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) and to describe factors predicting the main post-HCT complications. This retrospective study by the Europe
Autor:
Pierre Fenaux, Marie Robin
Publikováno v:
Leukemia. 34:2552-2560
Indications of allogeneic hematopoietic stem cell transplantation (HSCT) remain controversial in patients with lower risk myelodysplastic syndrome. We review prognostic factors in lower risk MDS, delineating patients with relatively poor risk who may
Autor:
Silke Heidenreich, Uwe Platzbecker, Marie Robin, Dietger Niederwieser, Dietrich W. Beelen, Arnon Nagler, Arnold Ganser, Johan Maertens, Arne Brecht, Nicolaus Kröger, Per Ljungman, Johannes Schetelig, Gérard Socié, Matthias Stelljes, Linda Koster, Antonin Vitek, Michel van Gelder, Liesbeth C. de Wreede, Jürgen Finke, Ghulam J. Mufti, Liisa Volin, Guido Kobbe, Ibrahim Yakoub-Agha, Thomas Luft
Publikováno v:
Leukemia, 33(3), 686-695. Nature Publishing Group
Leukemia
Leukemia, 33(3), 686-695
Leukemia
Leukemia, 33(3), 686-695
The causes and rates of late patient-mortality following alloHCT for myelodysplastic syndromes or secondary acute myeloid leukemia were studied, to assess the contribution of relapse-related, treatment-related, and population factors. Data from EBMT
Autor:
Aurore Perrot, Sylvain Thepot, Aliénor Xhaard, Lionel Adès, Gérard Socié, Raphaël Porcher, Anna D. Petropoulou, Patricia Ribaud, J Zhou, R P de Latour, Marie Robin
Publikováno v:
Leukemia. 24:1852-1858
Incidence on relapse and nonrelapse mortality (NRM) of chronic graft-versus-host disease (GVHD), per National Institutes of Health (NIH) criteria, is not well defined after reduced-intensity conditioning (RIC) regimens. We analyzed the association of
Autor:
Marie Robin, Eliane Gluckman, Helene Esperou, Philippe Guardiola, V. Rocha, Patricia Ribaud, S Shapiro, Gérard Socié, Agnès Devergie, M Yeshurun
Publikováno v:
Leukemia. 19(9)
We report long-term outcome in 102 patients with cCML transplanted from an HLA-identical sibling donor from 1982 to 1998. The conditioning regimen was based on cyclophosphamide associated with either total body irradiation (TBI) (37 patients) or with